ABIOMED, Inc. (ABMD) Shares Bought by Hamilton Lane Advisors LLC

Hamilton Lane Advisors LLC grew its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 50.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,241 shares of the medical equipment provider’s stock after acquiring an additional 7,827 shares during the period. ABIOMED comprises about 2.3% of Hamilton Lane Advisors LLC’s investment portfolio, making the stock its 13th biggest position. Hamilton Lane Advisors LLC owned about 0.05% of ABIOMED worth $4,356,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Seven Eight Capital LP purchased a new position in shares of ABIOMED in the second quarter valued at about $100,000. Crow Point Partners LLC purchased a new stake in shares of ABIOMED in the fourth quarter worth about $120,000. Rehmann Capital Advisory Group purchased a new stake in shares of ABIOMED in the third quarter worth about $202,000. Sigma Planning Corp purchased a new stake in shares of ABIOMED in the third quarter worth about $206,000. Finally, Dorsey & Whitney Trust CO LLC purchased a new stake in shares of ABIOMED in the third quarter worth about $215,000. Institutional investors and hedge funds own 90.75% of the company’s stock.

In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the sale, the vice president now directly owns 56,757 shares in the company, valued at $10,139,070.48. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Dorothy E. Puhy sold 6,364 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $179.08, for a total value of $1,139,665.12. Following the sale, the director now owns 39,532 shares in the company, valued at $7,079,390.56. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.

ABIOMED, Inc. (NASDAQ ABMD) traded up $6.04 during trading hours on Wednesday, hitting $224.13. The company had a trading volume of 535,188 shares, compared to its average volume of 265,664. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $9,910.00, a P/E ratio of 110.41, a P/E/G ratio of 2.84 and a beta of 0.15. ABIOMED, Inc. has a 12 month low of $103.53 and a 12 month high of $225.24.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The business had revenue of $132.80 million for the quarter, compared to the consensus estimate of $131.18 million. During the same period in the prior year, the business posted $0.20 earnings per share. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. equities research analysts predict that ABIOMED, Inc. will post 2.41 earnings per share for the current year.

ABMD has been the topic of a number of research analyst reports. SunTrust Banks initiated coverage on ABIOMED in a research report on Friday, September 29th. They issued a “buy” rating and a $195.00 target price on the stock. Jefferies Group boosted their target price on ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a research report on Friday, September 29th. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price on the stock in a research report on Tuesday, November 7th. Piper Jaffray Companies reiterated a “buy” rating on shares of ABIOMED in a research report on Thursday, January 4th. Finally, BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $199.67.

COPYRIGHT VIOLATION WARNING: This piece of content was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/01/17/abiomed-inc-abmd-shares-bought-by-hamilton-lane-advisors-llc.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply